Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Imetelstat

All Publications

Clinical Pharmacology of Imetelstat, a First-in-Class Oligonucleotide Telomerase Inhibitor

Imetelstat

Lennox, et. al.

Novel Nonlinear Population Pharmacokinetic Model of Imetelstat, a First-in-Class Oligonucleotide Telomerase Inhibitor

Imetelstat

González Sales, et. al.

Patient-Reported Outcomes Among Heavily Pretreated Patients With Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated With Imetelstat in IMerge

Clinical Imetelstat: MDS Imetelstat

Winter Heme 2024

Sekeres, et. al.

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence Across Different Risk Subgroups in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents in IMerge Phase 3 Study

Clinical Imetelstat: MDS Imetelstat

Komrokji, et. al.

Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated With Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database

Imetelstat Relevant MDS Publications

Komrokji, et. al.

Impact of Mutational Status on Clinical Response to Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Clinical Imetelstat: MDS Imetelstat

Santini, et. al.

Durable Continuous Transfusion Independence (TI) With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

Platzbecker, et. al.

Imetelstat in patients with lower-risk MDS who have relapsed or are refractory to erythropoiesis-stimulating agents in IMerge phase 3 trial

Clinical Imetelstat: MDS Imetelstat

The Lancet 2023

Platzbecker, et. al.

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia

Imetelstat Non-clinical Imetelstat

Nature Cancer 2023

Bruedigam, et. al.

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Clinical Imetelstat: MF Imetelstat

Frontiers in Oncology

Olschok, et. al.

[facetwp facet="publication_load_more"]